Publicacions en col·laboració amb investigadors/es de Instituto de Investigación Sanitaria de Navarra (20)

2024

  1. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

2023

  1. Preferential expression of SCN1A in GABAergic neurons improves survival and epileptic phenotype in a mouse model of Dravet syndrome

    Journal of Molecular Medicine, Vol. 101, Núm. 12, pp. 1587-1601

2022

  1. Adeno-Associated Viral Vectors as Versatile Tools for Neurological Disorders: Focus on Delivery Routes and Therapeutic Perspectives

    Biomedicines, Vol. 10, Núm. 4

  2. Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment

    Life, Vol. 12, Núm. 11

2021

  1. Adeno-associated viral vectors as versatile tools for parkinson’s research, both for disease modeling purposes and for therapeutic uses

    International Journal of Molecular Sciences, Vol. 22, Núm. 12

  2. Glucocerebrosidase gene therapy induces alpha-synuclein clearance and neuroprotection of midbrain dopaminergic neurons in mice and macaques

    International Journal of Molecular Sciences, Vol. 22, Núm. 9

2020

  1. Brain ventricular enlargement in human and murine acute intermittent porphyria

    Human molecular genetics, Vol. 29, Núm. 19, pp. 3211-3223

  2. Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates

    Brain Structure and Function, Vol. 225, Núm. 7, pp. 2153-2164

  3. Neuroanatomical tract-tracing techniques that did go viral

    Brain Structure and Function, Vol. 225, Núm. 4, pp. 1193-1224

2019

  1. Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine

    Movement Disorders, Vol. 34, Núm. 1, pp. 9-21

  2. Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease

    Molecular Neurobiology, Vol. 56, Núm. 8, pp. 5900-5910

2018

  1. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease

    GLIA, Vol. 66, Núm. 8, pp. 1752-1762

  2. Gene therapy approaches in the non-human primate model of Parkinson’s disease

    Journal of Neural Transmission, Vol. 125, Núm. 3, pp. 575-589

  3. Glucocerebrosidase Mutations and Synucleinopathies. Potential Role of Sterylglucosides and Relevance of Studying Both GBA1 and GBA2 Genes

    Frontiers in Neuroanatomy, Vol. 12

  4. History and future challenges of the subthalamic nucleus as surgical target: Review article

    Movement Disorders, Vol. 33, Núm. 10, pp. 1540-1550

2017

  1. Adeno-associated viral vectors serotype 8 for cell-specific delivery of therapeutic genes in the central nervous system

    Frontiers in Neuroanatomy, Vol. 11

2016

  1. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys

    Biomaterials, Vol. 110, pp. 11-23

  2. Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels

    Journal of Neurochemistry, Vol. 136, Núm. 2, pp. 403-415

2015

  1. Midbrain catecholaminergic neurons co-express α-synuclein and tau in progressive supranuclear palsy

    Frontiers in Neuroanatomy, Vol. 9, Núm. MAR

  2. Synaptic connectivity of the cholinergic axons in the olfactory bulb of the cynomolgus monkey

    Frontiers in Neuroanatomy, Vol. 9, Núm. MAR